Answers are grounded in this paper and cite their sources.
This phase III study of pafolacianine met its primary efficacy end point, identifying additional cancers not otherwise identified or planned for resection. Pafolacianine may offer an important real-time adjunct to current surgical approaches for ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Tanyi et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: